|
CXCR4-Targeting Molecules for Tumor Metastasis and PET Imaging
Application
Positron emission tomography (PET) imaging agents with high specificity for metastatic cancer.
Key Benefits
18F-labeled CXCR4 (partial) antagonist without stem cell mobilizing property is safe to be given to patient multiple times.
Identifies tumor location non-invasively and provides an indication of tumor’s metastatic potential.
Market...
Published: 4/23/2024
Contributor(s): Hyunsuk Shim, Mark Goodman, Dinesh Shetty, Yoon Hyeun Oum
|